Gambardella Valentina - Hospital Clínico Universitario de Valencia, University of Valencia

基本信息

浏览量：24

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 174 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

670P Phase I Trial of the Delta-Like Ligand-3 (DLL3)/CD3 IgG-Like T Cell Engager BI 764532 in Patients (pts) with DLL3-positive Tumors: Updated Data

M. Wermke,V. Gambardella, Y. Kuboki, E. Felip,M.F. Sanmamed,O. Alese,C.M. Sayehli,E. Arriola Aperribay, J. Wolf,L. Villaruz,M. Studeny, M. Bouzaggou, X. Fang,D. Morgensztern

Annals of Oncology (2024)

引用0浏览0引用

First-in-human Study (FIH) of FS222, a Next-Generation Tetravalent PD-L1/CD137 Bispecific Antibody: Safety, Pharmacodynamics (PD), and Antitumor Activity in Patients (pts) with Advanced Solid Tumors Including PD-1 Refractory Melanoma

Elena Garralda, Arjun Oberoi,Guillermo de Velasco,Ivan Victoria,David Pesantez, Inaki Eguren Santamaria,Victor Moreno,Valentina Boni,Andres Cervantes,Valentina Gambardella,Tudor-Eliade Ciuleanu,Milana Bergamino Sirven, Delvys Rodriguez-Abreu,Guzman Alonso,Laurentia Minea Gales,Daniel Jones,Abhay Patki, Ozlem Ataman,Ignacio Melero Bermejo

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

引用0浏览0引用

Abstract CT279: DareonTM-5: An open-label phase 2 trial of BI 764532, a DLL3-targeting T-cell engager, in patients (pts) with relapsed/refractory small cell lung cancer or other neuroendocrine carcinomas

Valentina Gambardella,Alastair Greystoke,Martin Reck,Meiruo Liu,Martha Mueller, Ulrich Duenzinger,Emily B. Bergsland,Taofeek Owonikoko

Cancer Researchno. 7_Supplement (2024)

引用0浏览0引用

583P COMPReS Study: Multiomic Profiling Reveals Organ-Specific Differences in Metastases and Identifies Novel Predictive Biomarkers in Relapsed Localized Colon Cancer

B. García-Mico,F. Gimeno-Valiente,J. Martin-Arana, B. Martínez-Castedo, D.G. Camblor, M. García-Bartolomé, B. Palomar, C. Martinez Ciarpaglini, M. Cabeza Segura,V. Gambardella, J.F. Català-Senent, D. Moro,S. Garcia-Botello, L. Pérez,S. Rosello Keranen,T.C. Fleitas, M. Huerta,D. Roda Perez, A. Cervantes,N. Tarazona Llavero

Annals of Oncology (2024)

引用0浏览0引用

613MO A Phase I Clinical Trial Evaluating Exarafenib, a Selective Pan-Raf Inhibitor in Combination with Binimetinib in NRAS-mutant (nrasmut) Melanoma (mel) & BRAF-altered Solid Tumors

P. Cassier,J.M. Mehnert, R. Kim,B. Chmielowski, M. Millward, C.A. Perez,M. Gonzalez Cao,V. Gambardella,M. Mckean,M.S. Brose, Y. Xing, G.V. Long, A. Kelly, G. Lee,P. Severson, R. Williams,C. Gaudy Marqueste

Annals of Oncology (2024)

引用0浏览0引用

1813Tip Debio 0123, a Highly Selective WEE1 Inhibitor, Combined with Carboplatin (CP) and Etoposide (ETOP) in Patients (pts) with Small Cell Lung Cancer (SCLC) That Progressed after Platinum-Based Therapy: A Phase I Dose Escalation and Expansion Study

V. Gambardella,A.F. Navarro Mendivil, J.M. Lopez-Picazo Gonzalez, P. Jain,G. Fernandez-Hinojal,M. De Miguel,J. Zugazagoitia, S. Gadgeel, S.A. Bhatti, A. Vilalta,E. Castanon Alvarez,P.F. Simoes da Rocha,S. Micallef, R. Frederiksen Franzen, L. Piggott,A. Bellon,E. Rodrigo Imedio,L.G. Paz-Ares

Annals of Oncology (2024)

引用0浏览0引用

612O Preliminary Results from a Phase I Study of CFT1946, a Novel BIDAC Degrader in Mutant BRAF V600 Solid Tumors

M. Vieito,M. Mckean,A.I. Spira, E. Rosen, J. Rodon,V. Moreno Garcia,V. Gambardella, O. Saavedra, S. Cousin, P. Cassier,I. Korakis,B.A. Van Tine, V.T-L. Ma, A. Ali, E. Hinojosa, R. Lobbardi, H. Liu, E. Hurh,L. Reyno,E. Buchbinder

Annals of Oncology (2024)

引用0浏览0引用

1006P Phase I Dose Escalation Study of HFB200603, a Best-in-class BTLA Antagonist Monoclonal Antibody (mab), in Monotherapy and in Combination with the Anti-Pd-1 Mab Tislelizumab (TIS) in Adult Patients (pts) with Advanced Solid Tumors

M. De Miguel, A. Landa Magdalena,V. Moreno Garcia,V. Gambardella,J. Menis, G. Daniele,A.B. El-Khoueiry,A.I. Spira, A. Gravina,A.J. Olszanski, O. Rapaic, J. Li, H. Poullain, G. Margall, G. Wong, W. Hedrich, J. Russella Pollard, J. Gan, X. Shi,R.H.I. Andtbacka

Annals of Oncology (2024)

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn